Chinese Journal of Tissue Engineering Research ›› 2024, Vol. 28 ›› Issue (7): 1137-1142.doi: 10.12307/2024.113

Previous Articles     Next Articles

Exosomes derived from mesenchymal stem cells in treatment of animals with acute liver failure: a meta-analysis

Ma Shuwei1, He Sheng2, Han Bing3, Zhang Liaoyun1   

  1. 1Department of Infectious Diseases, 2Department of Imaging, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China; 3School of Public Health, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
  • Received:2022-02-07 Accepted:2023-03-23 Online:2024-03-08 Published:2023-07-17
  • Contact: Zhang Liaoyun, Master, Professor, Chief physician, PhD supervisor, Department of Infectious Diseases, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
  • About author:Ma Shuwei, Master candidate, Department of Infectious Diseases, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
  • Supported by:
    the Shanxi Provincial Department of Science and Technology Project, No. 201903D421064 (to ZLY)

Abstract: OBJECTIVE: To evaluate the efficacy of exosomes derived from mesenchymal stem cells on animal models of acute liver failure.
METHODS: PubMed, Web of Science, Embase, The Cochrane Library, CBM, CNKI, WanFang, and VIP databases were retrieved from inception to January 16, 2023. A series of animal experiments on the treatment of acute liver failure animal models by exosomes derived from mesenchymal stem cells were collected. Two evaluators screened the literature and extracted the data independently. The bias risk was evaluated by the SYRCLE tool. The extracted data were analyzed by Revmen 5.4.1 software and Stata 17.0 software.
RESULTS: A total of 241 articles were retrieved and 9 animal experiments were included, with 219 animals: 110 animals in the model group and 109 animals in the exosome group. The results showed that the survival rate of animals in the exosome group improved significantly [RR=9.34, 95%CI(3.91, 22.29), P < 0.001], the levels of serum alanine transaminase [SMD=-5.31, 95%CI(-7.43, -3.19), P < 0.001] and aspartate aminotransferase [SMD=-4.47, 95%CI(-5.85, -3.10), P < 0.001] were reduced obviously. The expressions of interleukin-1β [SMD=-11.54, 95%CI(-18.12, -4.95), P=0.000 6], interleukin-6 [SMD=-5.75, 95%CI(-8.08, -3.41), P < 0.001] and tumor necrosis factor-α [SMD=-4.46, 95%CI(-6.83, -2.09), P=0.000 2], were suppressed obviously. 
CONCLUSION: Exosomes derived from mesenchymal stem cells effectively inhibit the inflammatory response, ameliorate liver function of animals with acute liver failure, and improve their survival rate. The results of subgroup analysis showed that the shorter survival time of animals (≤ 24 hours), the lower dose of transplanted exosomes (< 1 mg/kg) and the source of exosomes (adipose-derived mesenchymal stem cells) may affect the efficacy of the exosomes derived from mesenchymal stem cells in the animal model of acute liver failure. This conclusion and its clinical transformation still need to be confirmed by randomized controlled studies with large sample sizes and high quality.

Key words: mesenchymal stem cell, exosome, acute liver failure, animal, survival rate, liver function, systemic review, meta-analysis

CLC Number: